GlaxoSmithKline S.A.E (EGX:BIOC)
Egypt · Delayed Price · Currency is EGP 349.99
-0.12 (-0.03%)
At close: Oct 4, 2026
GlaxoSmithKline S.A.E Ratios and Metrics
Market cap in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 29,229 | 5,316 | 3,007 | 2,969 | 3,187 | 2,579 | |
Market Cap Growth | 463.23% | 76.81% | 1.27% | -6.84% | 23.57% | 82.08% |
Enterprise Value | 30,813 | 6,238 | 3,430 | 2,758 | 2,079 | 2,840 |
Last Close Price | 349.99 | 62.64 | 35.43 | 34.08 | 33.07 | 25.86 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 150.53 | 24.93 | 17.28 | 49.11 | 4.33 | 16.68 |
PS Ratio | 8.08 | 1.43 | 1.00 | 1.33 | 1.75 | 1.42 |
PB Ratio | 13.40 | 2.40 | 1.51 | 1.51 | 1.84 | 1.90 |
P/TBV Ratio | 13.40 | 2.40 | 1.51 | 1.51 | 2.00 | 2.31 |
P/FCF Ratio | - | 83.64 | - | 13.18 | 3.23 | 16.49 |
P/OCF Ratio | - | 22.07 | - | 9.82 | 3.08 | 13.42 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 8.52 | 1.67 | 1.15 | 1.23 | 1.14 | 1.57 |
EV/EBITDA Ratio | 65.25 | 23.53 | 7.36 | 5.71 | 42.79 | 10.20 |
EV/EBIT Ratio | 76.11 | 28.79 | 8.05 | 6.15 | 135.68 | 11.73 |
EV/FCF Ratio | - | 98.16 | - | 12.25 | 2.11 | 18.15 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.82 | 0.04 | 0.06 | 0.05 | 0.04 | 0.13 |
Debt / EBITDA Ratio | 3.94 | 0.29 | 0.25 | 0.20 | 1.07 | 0.60 |
Debt / FCF Ratio | - | 1.29 | - | 0.43 | 0.07 | 1.15 |
Net Debt / Equity Ratio | 0.73 | -0.18 | 0.02 | -0.37 | -0.30 | 0.08 |
Net Debt / EBITDA Ratio | 3.59 | -1.50 | 0.09 | -1.52 | -10.62 | 0.38 |
Net Debt / FCF Ratio | -1.22 | -6.26 | -0.08 | -3.25 | -0.52 | 0.68 |
Asset Turnover | 0.71 | 0.92 | 0.83 | 0.66 | 0.65 | 0.80 |
Inventory Turnover | 1.55 | 2.58 | 2.51 | 2.46 | 2.57 | 2.31 |
Quick Ratio | 0.39 | 0.57 | 0.59 | 1.01 | 0.95 | 0.73 |
Current Ratio | 1.23 | 1.62 | 1.82 | 1.88 | 1.76 | 1.53 |
Return on Equity (ROE) | 9.15% | 10.12% | 8.79% | 3.27% | -7.38% | 12.03% |
Return on Assets (ROA) | 4.75% | 3.32% | 7.38% | 8.32% | 0.34% | 6.66% |
Return on Invested Capital (ROIC) | 12.27% | 7.36% | 13.37% | 18.54% | 1.15% | 14.91% |
Return on Capital Employed (ROCE) | 17.60% | 9.50% | 20.50% | 22.10% | 0.90% | 17.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 0.66% | 4.01% | 5.79% | 2.04% | 23.08% | 6.00% |
FCF Yield | -4.46% | 1.20% | -17.58% | 7.58% | 30.98% | 6.07% |
Dividend Yield | 0.21% | 1.20% | 2.82% | 2.20% | - | 2.90% |
Payout Ratio | 51.48% | 6.63% | 40.05% | 217.67% | 15.10% | 3.61% |
Total Shareholder Return | 0.29% | 1.20% | 2.82% | 2.20% | - | 2.90% |